Related Experiment Video

Updated: Apr 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Interleukin-6 promotor polymorphisms and coronary vasospastic angina in Han Chinese

Ying Wang1, Gang Li1, Ya-Min Su2

  • 1Department of Cardiology, Third People's Hospital of Nantong and Third Affiliated Hospital of Nantong University Nantong 226001, P. R. China.

International Journal of Clinical and Experimental Medicine
|October 31, 2014
PubMed

Insights

The Interleukin-6 (IL-6) -634C/G gene polymorphism is linked to coronary vasospastic angina (CVA) in Han Chinese individuals. The G allele of this IL-6 polymorphism increases the risk of developing CVA.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Immunology

Background:

  • Inflammation plays a role in the development of coronary vasospastic angina (CVA).
  • Interleukin-6 (IL-6) is a key cytokine involved in inflammatory processes, with both pro- and anti-inflammatory effects.
  • Genetic variations in inflammatory mediators may influence susceptibility to cardiovascular diseases like CVA.

Purpose of the Study:

  • To investigate the association between the -634C/G polymorphism of the Interleukin-6 (IL-6) gene and coronary vasospastic angina (CVA) in the Han Chinese population.
  • To determine if specific genotypes or alleles of the IL-6 gene are risk factors for CVA.

Main Methods:

  • A case-control study was conducted with 27 CVA patients and 232 healthy controls.
  • Genotyping for the IL-6 -634C/G polymorphism was performed using the PCR-based restriction fragment length polymorphism (PCR-RFLP) technique.
  • Statistical analysis was used to compare genotype and allele frequencies between the CVA and control groups.

Main Results:

  • The distribution of IL-6 -634C/G genotypes differed significantly between CVA patients and controls (P = 0.0080).
  • The frequency of the G allele was significantly higher in the CVA group (38.89%) compared to the control group (21.98%) (P = 0.0057).
  • Carriers of the G allele (CG and GG genotypes) exhibited an increased risk of CVA compared to the wild type CC genotype.

Conclusions:

  • The IL-6 -634C/G polymorphism is significantly associated with coronary vasospastic angina (CVA) in the Han Chinese population.
  • The G allele of the IL-6 -634C/G polymorphism represents an independent risk factor for the development of CVA.
  • These findings highlight the role of genetic variations in IL-6 in the pathogenesis of CVA.

Keywords:
ChineseInterleukin-6coronary vasospastic anginagenetic polymorphism

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

912

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113